Suvratoxumab is a Monoclonal Antibody owned by Aridis Pharmaceuticals, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.

Suvratoxumab acts against Staphylococcus aureus alpha toxin. Staphylococcus aureus alpha toxin (AT) is a bacterial exotoxin that induces substantial tissue and organ damage. Alpha-toxin in the blood impairs the intestinal epithelial barrier and thereby facilitate the translocation of luminal bacteria into the blood, which in turn aggravates the disease condition. MEDI-4893 shows its therapeutic effect by inhibiting alpha toxin.

The revenue for Suvratoxumab is expected to reach a total of $345m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Suvratoxumab NPV Report.

Suvratoxumab was originated by MedImmune and is currently owned by Aridis Pharmaceuticals.

Suvratoxumab Overview

Suvratoxumab (MEDI-4893) is under development for the prevention of ventilator associated pneumonia caused by Staphylococcus aureus. The drug candidate is administered intravenously in the form of solution. It is a potent human Immunoglobulin G (IgG)1 monoclonal antibody that binds to an alpha toxin released by Staphylococcus aureus. It is a new molecular entity.

Aridis Pharmaceuticals Overview

Aridis Pharmaceuticals (Aridis) is a biopharmaceutical company. The company develops novel, differentiated therapies for infectious diseases. Its pipeline products include AR-301 mAb, AR-105 mAb, AR-101 mAb, AR-501(Gallium Citrate), AR-401 mAb and AR-201 mAb. The company uses a disruptive platform technology to discover potent human monoclonal antibodies from patients. Its proprietary platform, MabIgXis used to discover potent therapeutic antibodies for any diseases and to generate an unrivaled product portfolio ofanti-infective mAbs. The company also works on macromolecular stabilization technology for increase the stability of vaccines. Aridis is headquartered in San Jose, California, the US

The company reported revenues of (US Dollars) US$1.5 million for the fiscal year ended December 2021 (FY2021), an increase of 53.5% over FY2020. The operating loss of the company was US$42 million in FY2021, compared to an operating loss of US$22.4 million in FY2020. The net loss of the company was US$42.2 million in FY2021, compared to a net loss of US$22.3 million in FY2020. The company reported revenues of US$0.4 million for the third quarter ended September 2022, an increase of 36.6% over the previous quarter.

Quick View – Suvratoxumab

Report Segments
  • Innovator
Drug Name
  • Suvratoxumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.